Ingber D.E
ADA: Once-Weekly Cagrilintide + Semaglutide Promising in Type 2 Diabetes FRIDAY, June 12, 2026 -- Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter 2 inhibitor (SGLT2i), and using basal insulin, according to three studies published online June 7 in The Lancet Diabetes & Endocrinology and The Lancet to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans
When you come to us, you can expect: Trustworthy Advice : Our pharmacists are here to answer your questions, discuss your health history, and ensure you understand your medication, including potential risks and benefits
Weight loss plateaus Every patient on a GLP-1 will eventually stop losing weight
Track: Weekly weight (same day, same time, same conditions) Measurements (waist, hips, chestmore reliable than scale alone) Side effects (what you feel, when, how severe) Food intake (even rough estimates help) PeptIQ makes this simplelog doses, track inventory, monitor your response over time
